



D Wallwiener

Contact

D Wallwiener

Publications (32)

Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober J, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. *ESMO Open* 2021; 6:100299.

Winder F, Magerle M, Wenzl R, Wallwiener D (2020). Die Zukunft der operativen Gynäkologie. Presented at: 34. Arlberger Gynäkologielehrgang: Neuerungen, Schwerpunkte und Leitlinien, Zürs am Arlberg

Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. *Ann Oncol* 2017; 28:2899.

Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates R, Kreipe H, Hartmann A, Pelz E, Erber R, Harbeck N. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. *Ann Oncol* 2016; 27:1035-1040.

Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. *Ann Oncol* 2014; 25:1551-7.

Solomayer E, Wallwiener D, Wackwitz B, Krämer B, Huober J, Becker S, Lück H, Janni W, Hirnle P, Gebauer G, Fehm T. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. *Ann Oncol* 2012; 23:2271-2277.

Huober J, Nimmrich I, May C, Beckmann M, Baumgärtner A, Kubista E, Ragosch V, Azim H, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. *Breast* 2011; 21:27-33.

Kraemer B, Guengoer E, Solomayer E, Wallwiener D, Hornung R. Stage I carcinoma of the Bartholin's gland managed with the detection of inguinal and pelvic sentinel lymph node. *Gynecol Oncol* 2009; 114:373-374.

Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober J. Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2007; 18:1981-4.

Krauss K, Bachmann C, Hartmann J, Siegmann K, Sotlar K, Wallwiener D, Huober J. Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole. *Anticancer research* 2007; 27:3477-80.

Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]. *Zentralblatt für Gynäkologie* 2006; 128:30-7.

Krauss K, Wallwiener D, Huober J. Neue Aspekte der adjuvanten Therapie beim Mammakarzinom - die Aromatasehemmer. Geburtsh Frauenheilk 2005; 65:803-805.

Schneeweiss A, Wallwiener D, Hamerla R, Solomayer E, Krauss K, Beldermann F, Rudlowski C, von Fournier D, Sinn H, Huober J, Bastert G. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. European journal of cancer (Oxford, England : 1990) 2004; 40:2432-8.

Krauss K, Aydeniz B, Dohmen B, Wehrmann M, Wallwiener D, Huober J. Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:2966-8.

Seeger H, Huober J, Wallwiener D, Mueck A. Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2004; 36:277-80.

Mueck A, Seeger H, Wallwiener D, Huober J. Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutics in the treatment of human ovarian cancer? Preliminary in vitro investigations. European journal of gynaecological oncology 2004; 25:699-701.

Krainick-Strobel U, Bergmann A, Huober J, Wallwiener D. Aktueller Stellenwert des Ultraschalls in der Mammadiagnostik. Geburtsh Frauenheilk 2004; 64:632-633.

Seeger H, Diesing D, Gückel B, Wallwiener D, Mueck A, Huober J. Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation. The Journal of steroid biochemistry and molecular biology 2003; 84:255-7.

Wallwiener D, Huober J. St. Gallen 2003 – Was tun?. Frauenarzt 2003; 44:516-517.

Gückel B, Stumm S, Kayser S, Rentzsch C, Gruber I, Marmé A, Huober J, Meuer S, Wallwiener D. [CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]. Zentralblatt für Gynäkologie 2002; 124:566-73.

Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. Journal of cancer research and clinical oncology 2002; 128:153-60.

Huober J, Wallwiener D. Mammakarzinom in der Schwangerschaft. Geburtsh Frauenheilk 2002; 62:904-906.

Huober J, Wagner U, Wallwiener D. Der Stellenwert von Aromastasehemmern der dritten Generation in der endokrinen Therapie des Mammakarzinoms - Zeit zum Umdenken. Geburtsh Frauenheilk 2002; 62:15-21.

Wagner U, Krebs D, Bauknecht T, Kreienberg R, Möbus V, Biersack H, Schlebusch H, Renke K, Huober J, Giffels P, Reinartz S, Köhler S, Wallwiener D. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Clinical cancer research : an official journal of the American Association for Cancer Research 2001; 7:1154-62.

Huober J, Meyer A, Wagner U, Wallwiener D. Primäre Chemotherapie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom. Med. Welt 2001; 52:101-105.

Huober J, Meyer A, Wagner U, Wallwiener D. Qualitätssicherung in der operativen Therapie von Ovarialtumoren. Med. Welt 2001; 52:184-187.

Meyer A, Huober J, Krainick-Strobel U, Greb R, Wagner U, Wallwiener D. Die neoadjuvante endokrine Therapie des Mammakarzinoms. Onkologe 2000; 1:67-71.

Hohaus S, Wallwiener D, Martin S, Voso M, Huober J, Fersis N, Bastert G, Haas R. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Seminars in oncology 1998; 25:7-11; discussion 45-8.

Huober J, Haas R, Bastert G, Goldschmidt H, Martin S, Meyer A, Wittmann G, Hohaus S, Schneeweiss A, Wallwiener D. Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. Journal of cancer research and clinical oncology 1998; 124:690-4.

Huober J, Holz F, Schmid H, Nölle B, Bellmann C, Krastel H, Wallwiener D, Bastert G. [Paraneoplastic retinopathy in 2 patients with breast carcinoma]. Zentralblatt für Gynäkologie 1997; 119:278-81.

Huober J, Grischke E, Hahn U, Wallwiener D, Bastert G. Post partum Hysterektomie bei 2 Patientinnen mit Placenta percreta. Gynäkolo. prax 1997; 21:685-689.

Costa S, von Minkwitz G, Gremm B, Huober J, Fersis N, Schmid H, Wallwiener D, Müller H, Eppenberger U, Diel I, Kaufmann M, Bastert G. Klinisch relevante Prognosefaktoren beim Mammakarzinom. Klin Lab 1994; 40:1153-1166.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch